SavedAdd your journal

Journals / Astım Allerji İmmünoloji / 2021 / Cilt: 19 - Sayı: 3

Management of Patients with Hereditary Angioedema During the COVID-19 Pandemic

Fatih Çölkesen
Eray YILDIZ
Şevket Arslan
Recep Evcen
Filiz Sadi Aykan
Mehmet Kılınç
Pages
166–175
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Considering their beneficial effects on COVID-19, it is recommended that HAE patients should continue the use of agents blocking the kallikrein-kinin system.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study was to determine the clinical course and treatment outcomes of patients with hereditary angioedema (HAE) after infection with coronavirus disease 2019 (COVID-19).
📊
Key Findings & Data:These patients were regularly followed up over phone calls since the first COVID-19 case was seen in our country.
💡
Conclusion & Impact:Considering their beneficial effects on COVID-19, it is recommended that HAE patients should continue the use of agents blocking the kallikrein-kinin system.
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study was to determine the clinical course and treatment outcomes of patients with hereditary angioedema (HAE) after infection with coronavirus disease 2019 (COVID-19). Materials and Methods: Thirty-nine patients with HAE were included in this study. These patients were regularly followed up over phone calls since the first COVID-19 case was seen in our country. Patients were asked to visit the hospital if there was a history of contact with a confirmed COVID-19 patient or if the patient developed clinical symptoms of COVID-19. Results: There were 21 (54%) patients with type I HAE, and 18 (46%) with type II HAE. All patients received treatment for angioedema attacks (C1-inhibitor [C1-INH], icatibant), and seven (20%) received long-term prophylaxis (danazol). Treatment for attacks was continued for all patients during the pandemic. Patients taking danazol were switched to long-term prophylaxis using the C1-INH concentrate. Eleven (28%) patients with HAE developed COVID-19 during this study. Only one patient had severe COVID-19. Six patients (54.5%) were diagnosed with type II HAE, and five (45.5%) were diagnosed with type I HAE. The most common COVID-19 symptoms were fever (7/11; 64%) and myalgia (6/11; 55%). Mild angioedema attacks were experienced by 36% (4/11) of the HAE patients diagnosed with COVID-19. Icatibant was used in all patients. Conclusion: Agents used for HAE block the kallikrein-kinin system and may be useful in the treatment of COVID-19. Considering their beneficial effects on COVID-19, it is recommended that HAE patients should continue the use of agents blocking the kallikrein-kinin system.

🔖

Cite This Article

Çölkesen, F., YILDIZ, E., Arslan, Ş., Evcen, R., Aykan, F. S., Kılınç, M. (2022). Management of Patients with Hereditary Angioedema During the COVID-19 Pandemic. Astım Allerji İmmünoloji, Cilt: 19 - Sayı: 3, 166–175. https://ajindex.com/articles/451090

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Aycan Aşık NMG. COVID-19 disease and hereditary angioedema. Asthma Allergy Immunology 2020;18:19-22
  2. Aygoren-Pursun E, Bork K. Hereditary angioedema. Internist (Berl) 2019;60(9):987-95
  3. Zeerleder S, Levi M. Hereditary and acquired C1-inhibitor- dependent angioedema: From pathophysiology to treatment. Ann Med 2016;48(4):256-67
  4. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 2005;11(8):875-9
  5. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181(2):271-80.e8
  6. Sodhi CP, Wohlford-Lenane C, Yamaguchi Y, Prindle T, Fulton WB, Wang S, et al. Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg(9) bradykinin/BKB1R axis and facilitates LPS-induced neutrophil infiltration. Am J Physiol Lung Cell Mol Physiol 2018;314(1):L17-L31
  7. Jia H. Pulmonary angiotensin-converting enzyme 2 (ACE2) and inflammatory lung disease. Shock 2016;46(3):239-48
  8. Caballero T, Maurer M, Longhurst HJ, Aberer W, Bouillet L, Fabien V. Triggers and prodromal symptoms of angioedema attacks in patients with hereditary angioedema. J Investig Allergol Clin Immunol 2016;26(6):383-6
  9. Bousfiha A, Jeddane L, Picard C, Al-Herz W, Ailal F, Chatila T, et al. Human inborn errors of immunity: 2019 update of the IUIS phenotypical classification. J Clin Immunol 2020;40(1):66- 81
  10. Xu Y, Liu S, Zhang Y, Zhi Y. Does hereditary angioedema make COVID-19 worse? World Allergy Organ J 2020;13(9):100454
  11. National Institutes of Health. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Access date: 11 June 2020. Available from:
  12. Polycarpou A, Howard M, Farrar CA, Greenlaw R, Fanelli G, Wallis R, et al. Rationale for targeting complement in COVID-19. EMBO Mol Med 2020;12(8):e12642
  13. Mansour E, Palma AC, Ulaf RG, Ribeiro LC, Bernardes AF, Nunes TA, et al. Safety and Outcomes Associated with the Pharmacological Inhibition of the Kinin-Kallikrein System in Severe COVID-19. Viruses 2021;13(2):309
  14. Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. J Allergy Clin Immunol Pract 2021;9(1):132-150.e3
  15. Valerieva A, Nedeva D, Yordanova V, Pe